Page 40 - Read Online
P. 40

Page 6 of 8                                                                                 Balzano et al. Mini-invasive Surg 2021;5:41  https://dx.doi.org/10.20517/2574-1225.2021.49


                             Table 2. Robotic radical cystectomy with extracorporeal urinary diversion operative and post-operative characteristics

                                                                                                   Complication rate        Complication rate        GI                                      Continence (0-1
                                                   Length of surgery (min)  Length of stay                                                                            Overall complication
                              Study           N                                                    Clavien 1-2 90d/30d      Clavien 3-5 90d/30d      complications                           pad/d) (day %/night
                                                   (median/mean)            (mean/median days)                                                                        rate 90d/30d (%)
                                                                                                   (%)                      (%)                      (%)                                     %)
                                         [5]
                              Hussein et al.    486 401/-                   -/8                    -                        12/10                    20               35/28                  -
                              2018
                                          [23]
                              Mazzone et al.    105 350/-                   -/13                   -                        -/42.9                   -                -                      -
                              2021
                                        [10]
                              Lenfant et al.     34  285/-                  -/12                   11.7/32.4                17.6/5.9                 -                29.4/38.2              -
                              2018
                                       [14]
                              Zhang et al.     375 421/-                    7/-                    -                        24.8/17.9                29.3             48.3/43.2              -
                              2020
                                      [15]
                              Shim et al.     278 -/510                     22.4/-                 41/-                     20.5/-                   12.9             61.5/-                 -
                              2020
                                          [25]
                              Mistretta et al.    44  -                     -                      -                        -                        -                -                      63.8/51.6
                              2021
                                    [28]
                              Lin et al.   2008 108 -/330                   -                      -                        -                        -                18.5                   90.7/82.6



                             this growing body of evidence, the paucity of level one evidence limits our ability to draw definitive conclusions.




                             CONCLUSIONS
                             RARC has taken over as the treatment of choice in most cases in the treatment of muscle-invasive bladder cancer. As intracorporeal urinary diversion
                             continues to gain popularity, we need to continue to challenge the data and evaluate if we are making the right decision for our patients. After looking across
                             the data provided worldwide, there continues to be a reason to pause with the sweeping adoption of the intracorporeal urinary diversion with continued varied

                             data of the superiority of outcomes.



                             DECLARATIONS
                             Authors’ contributions
                             Balzano FL and Chan KG contributed equally to all components of the manuscript.



                             Availability of data and materials
                             Not applicable.
   35   36   37   38   39   40   41   42   43   44   45